News >

Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC

Gina Columbus
Published: Monday, Nov 13, 2017

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MD
The National Comprehensive Cancer Network (NCCN) unveiled its latest treatment guidelines for patients with varying histologies of non–small cell cancer (NSCLC), including those who are EGFR-mutation positive.1 One of the notable updates in this area, explained Suresh A. Ramalingam, MD, is the category 2A recommendation to give osimertinib (Tagrisso), a third-generation irreversible EGFR inhibitor designed to inhibit both EGFR-sensitizing and EGFR T790M-resistance mutations, in the first-line setting for patients whose disease is EGFR mutant.

-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.

OncLive: Regarding EGFR-mutant NSCLC, what are the most notable updates to the NCCN guidelines?

Ramalingam: The most important update is the introduction of osimertinib in the frontline space, and that follows the FLAURA data that we presented at the 2017 ESMO Congress a couple of months ago. That study compared osimertinib to erlotinib or gefitinib for first-line therapy in patients with either exon 19 and 21 alterations. That study showed superiority for osimertinib; the median PFS was improved from 10.2 months [with standard therapy] to 18.9 months. The hazard ratio was 0.46.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x